TGFB1 and metabolic dysfunction-associated steatotic liver disease: It has been suggested that blood levels of TGF-β in patients with non-alcoholic fatty liver disease may be an effective biomarker of coronavirus disease 2019 (COVID-19) severity and adverse outcomes [66].